Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis
详细信息 查看全文
- 作者：Maria Lorenzi ; Uffe Jon Ploug ; Jakob Langer ; Rasmus Skovgaard…
- 关键词：Network meta ; analysis ; Liraglutide ; SGLT ; 2 ; Comparative efficacy ; HbA1c ; Weight ; Fasting plasma glucose
- 刊名：Diabetes Therapy
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：8
- 期：1
- 页码：85-99
- 全文大小：1050KB
- 刊物主题：Internal Medicine; Diabetes; Cardiology; Endocrinology;
- 出版者：Springer Healthcare
- ISSN：1869-6961
- 卷排序：8
文摘
IntroductionFor people with type 2 diabetes (T2DM) inadequately controlled with oral antidiabetic drugs (OADs), evidence from both randomized controlled trials (RCTs) and real-world studies has demonstrated that treatment intensification with liraglutide offers effective glycemic control, weight reduction, and a lower risk of hypoglycemia compared to treatment intensification with insulin or additional OADs. Sodium glucose cotransporter 2 (SGLT-2) inhibitors are a new class of OADs that have also been shown to be effective in T2DM patients inadequately controlled with OADs. Currently there are no head-to-head RCTs comparing these to liraglutide.